ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB484

Understanding What Patients and Families Living with Kidney Failure Want and Need to Know about Xenotransplantation: A Kidney Transplant Research Possibility

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Hilliard-Boone, Tandrea, American Institutes for Research, Chicago, Illinois, United States
  • DePatie, Holly, American Institutes for Research, Chicago, Illinois, United States
Background

Advances in xenotransplantation offer great promise for an alternative supply of organs to meet the needs of people with life-threatening illnesses like kidney failure. However, this kidney transplant possibility has not yet been tested in clinical trials with humans, only early testing. The American Society of Nephrology (ASN) Kidney Health Initiative (KHI) formed a project team to assess perspectives about xenotransplantation and identify information needed to help ensure that future first-in-human (FIH) clinical studies are patient-centered and reflect the perspectives of those most affected by the research.

Methods

To understand what is most important for patients and families living with kidney failure to know about xenotransplantation and future clinical trials, the American Institutes of Research (AIR) conducted 39 virtual individual interviews with patients, care partners, and nephrologists between April 1, 2022 and May 14, 2022. We used qualitative thematic analysis to synthesize and cross-validate the data.

Results

Patients, care partners, and nephrologists shared perceived benefits of xenotransplantation, including expanding the supply of organs available, reducing long waiting times, and improving quality of life. Perceived risks included organ rejection, infection, or other complications. Nephrologists identified potential risks associated with a lack of available data related to short-and long-term health outcomes and safety. All participants expressed a need for information about xenotransplantation that is transparent, accessible, and understandable for diverse audiences and recommended strategies to help prepare clinicians to have conversations with patients and families about future clinical trials.

Conclusion

Breakthroughs in xenotransplantation offer great promise for addressing the critical organ donor shortage, particularly for those living with kidney failure. Our discussions with patients, care partners, and nephrologists underscore the need to prepare both clinicians and families for discussions about potential participation in a clinical trial for xenotransplantation.